- Home
- OPBK vs ARTV Comparison
OPBK vs ARTV Comparison
Compare OPBK & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- ARTV
- Stock Information
- Founded
- OPBK 2005
- ARTV 2019
- Country
- OPBK United States
- ARTV United States
- Employees
- OPBK N/A
- ARTV N/A
- Industry
- OPBK Major Banks
- ARTV
- Sector
- OPBK Finance
- ARTV
- Exchange
- OPBK Nasdaq
- ARTV NYSE
- Market Cap
- OPBK 213.7M
- ARTV 186.1M
- IPO Year
- OPBK 2018
- ARTV 2024
- Fundamental
- Price
- OPBK $11.86
- ARTV $3.00
- Analyst Decision
- OPBK Hold
- ARTV Strong Buy
- Analyst Count
- OPBK 1
- ARTV 7
- Target Price
- OPBK $18.00
- ARTV $20.00
- AVG Volume (30 Days)
- OPBK 36.0K
- ARTV 133.1K
- Earning Date
- OPBK 04-24-2025
- ARTV 05-22-2025
- Dividend Yield
- OPBK 3.99%
- ARTV N/A
- EPS Growth
- OPBK N/A
- ARTV N/A
- EPS
- OPBK 1.39
- ARTV N/A
- Revenue
- OPBK $79,278,000.00
- ARTV $251,000.00
- Revenue This Year
- OPBK $16.70
- ARTV N/A
- Revenue Next Year
- OPBK $12.07
- ARTV N/A
- P/E Ratio
- OPBK $8.65
- ARTV N/A
- Revenue Growth
- OPBK N/A
- ARTV N/A
- 52 Week Low
- OPBK $8.91
- ARTV $2.92
- 52 Week High
- OPBK $18.57
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- OPBK 35.93
- ARTV N/A
- Support Level
- OPBK $12.18
- ARTV N/A
- Resistance Level
- OPBK $12.07
- ARTV N/A
- Average True Range (ATR)
- OPBK 0.28
- ARTV 0.00
- MACD
- OPBK 0.02
- ARTV 0.00
- Stochastic Oscillator
- OPBK 18.52
- ARTV 0.00
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.